In this review:
12-year follow-up data from GETUG-12
Combining AR-targeted therapy with radium-223 in mCRPC
Sequencing therapy in poor prognosis mCRPC
Rucaparib shows promise in mCRPC with HRR gene alterations
Dose-escalation of 177Lu-PSMA- 617: promising data in mCRPC
Apalutamide and enzalutamide in non-mCRPC
Prostate RT improves survival in low-volume disease
Abiraterone benefits mHSPC
Early enzalutamide use looks promising in mHSPC
Comprehensive genomic profiling defines therapy for metastatic disease
Please login below to download this issue (PDF)